You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Single-cell RNA sequencing uncovered interactions between colorectal cancer alterations and corresponding immune cell and stromal features.
The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.
Research institutions in the US and Europe will lead the studies, which will explore different aspects of COVID-19 such as host immune response.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.
Agilent, which co-led Mission Bio's 2018 $30 million Series B financing round, will comarket the Tapestri platform to cancer researchers in North America.
The researchers identified specific macrophage and conventional dendritic cell subsets as key mediators of cellular crosstalk in the tumor microenvironment.
Both studies emerged from the ongoing Human Cell Atlas project and could help scientists decide on the best approaches to use in various contexts.
The alliance, led by Singapore-based startup Proteona, also includes several organizations from that city state as well as German research institutes.
The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.
Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.
The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.
Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.
In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.